Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

Celldex Therapeutics has seen a mixed share price story in recent years, and that uneven record puts the spotlight on whether the current market value still lines up with what its balance sheet supports. With fresh shareholder litigation headlines now in the mix, the question for you is how much of today’s price rests on expectations that sit beyond the company’s book value. Over the past 5 years the stock has fallen 41.9%, which puts long term holders squarely on the issue of whether the...